The primary glucose-lowering effect of metformin resides in the gut, not the circulation: Results from short-term pharmacokinetic and 12-week dose-ranging studies

Diabetes Care

Volumn 39, Issue 2, 2016, Pages 198-205

  Buse, John B ^a   DeFronzo, Ralph A ^b   Rosenstock, Julio ^c   Kim, Terri ^d   Burns, Colleen ^d   Skare, Sharon ^d   Baron, Alain ^d   Fineman, Mark ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^d Elcelyx Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL;

ARTICLE; CIRCULATION; DELAYED RELEASE FORMULATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FATALITY; DRUG POTENCY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTESTINE; LACTIC ACIDOSIS; LARGE INTESTINE; MULTICENTER STUDY (TOPIC); NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; VOMITING; ADOLESCENT; ADULT; AGED; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GASTROINTESTINAL TRACT; HYPERGLYCEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GASTROINTESTINAL TRACT; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; YOUNG ADULT;

EID: 84962094356     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0488     Document Type: Article

References (40)

1. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10:143-156
2. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glu-cagon signalling by decreasing production of cyclic AMP. Nature 2013;494:256-260
3. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of met-formin action. J Clin Invest 2001;108:1167-1174
4. Madiraju AK, Erion DM, Rahimi Y, et al. Met-formin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014;510:542-546
5. Stepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 2002;30:861-868
6. Bonora E, Cigolini M, Bosello O, et al. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, gluca-gon and growth hormone in non-diabetic subjects. Curr Med Res Opin 1984;9:47-51
7. Napolitano A, Miller S, Nicholls AW, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One 2014;9:e100778
8. Shin NR, Lee JC, Lee HY, etal.Anincreaseinthe Akkermansia spp. population induced by metfor-min treatment improves glucose homeostasis in diet-induced obese mice. Gut 2014;63:727-735
9. Vidon N, Chaussade S, Noel M, Franchisseur C, Huchet B, Bernier JJ. Metformin in the digestive tract. Diabetes Res Clin Pract 1988;4:223-229
10. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-246
11. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmaco-kinet 2011;50:81-98
12. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia 2008;51:1552-1553
13. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103:491-497
14. Hong Y, Rohatagi S, Habtemariam B, Walker JR, Schwartz SL, Mager DE. Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol 2008;48:696-707
15. Glucophage (Metformin Hydrochloride) Tablets; Glucophage XR (Metformin Hydrochloride) Extended-Release Tablets [package insert]. Princeton, NJ, Bristol-Myers Squibb Company, 2009
16. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
17. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes melli-tus. J Clin Endocrinol Metab 1996;81:4059-4067
18. Wilcock C, Bailey CJ. Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol 1991;43:120-121
19. Beckmann R. Absorption, distribution in the organism and elimination of metformin. Diabe-tologia 1969;5:318-324
20. Migoya EM, Bergeron R, Miller JL, et al. Di-peptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010;88:801-808
21. Hundal RS, Krssak M, Dufour S, et al. Mech anism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49: 2063-2069
22. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-579
23. Habib AM, Richards P, Rogers GJ, Reimann F, Gribble FM. Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia 2013;56:1413-1416
24. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-494
25. Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 2004;17:336-342
26. Molloy AM, Ardill J, Tomkin GH. The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects. Diabetologia 1980; 19:93-96
27. Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002;298:779-784
28. Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 2005;128:97-107
29. Donath MY, Burcelin R. GLP-1 effects on islets: hormonal, neuronal, or paracrine? Diabetes Care 2013;36(Suppl. 2):S145-S148
30. Bohórquez DV, Shahid RA, Erdmann A, et al. Neuroepithelial circuit formed by innervation of sensory enteroendocrine cells. J Clin Invest 2015;125:782-786
31. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124 (Suppl.):S3-S18
32. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18:779-784
33. Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lacticacidosis: a prognostic and therapeutic study. Crit Care Med 2009; 37:2191-2196
34. Al-Abri SA, Hayashi S, Thoren KL, Olson KR. Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs. Clin Toxicol (Phila) 2013;51:444-447
35. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925-927
36. Misbin RI, Green L, Stadel BV,Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-266
37. Peters N, Jay N, Barraud D, et al. Metformin-associated lactic acidosis in an intensive care unit. Crit Care 2008;12:R149
38. Almirall J, Bricullé M, Gonzalez-Clemente JM. Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice. Nephrol Dial Transplant 2008;23:2436-2438
39. Lucis OJ. The status of metformin in Canada. Can Med Assoc J 1983;128:24-26
40. Jones GC, Sainsbury CA. Comment on "A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure." Diabet Med 2015;32:287